PE20100742A1 - NEW PROCEDURES AND FORMULATIONS - Google Patents
NEW PROCEDURES AND FORMULATIONSInfo
- Publication number
- PE20100742A1 PE20100742A1 PE2010000446A PE2010000446A PE20100742A1 PE 20100742 A1 PE20100742 A1 PE 20100742A1 PE 2010000446 A PE2010000446 A PE 2010000446A PE 2010000446 A PE2010000446 A PE 2010000446A PE 20100742 A1 PE20100742 A1 PE 20100742A1
- Authority
- PE
- Peru
- Prior art keywords
- mannitol
- sorbitol
- lactose
- cellulose
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA DE LIBERACION MANTENIDA QUE COMPRENDE: A) 8-(2,6-DIFLOROFENIL)-4-(4-FLUORO-2-METILFENIL)-2-{[2-HIDROXI-1-(HIDROXIMETIL)ETIL]AMINO}PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONA EN UNA PROPORCION 2,5% EN PESO; B) 10 A 70% EN PESO DE POLIMERO RETARDADOR DE LA LIBRACION SELECCIONADOS ENTRE METILCELULOSA SODICA, HIDROXIPROPIL-CELULOSA, CARBOXIMETILAMIDA, ENTRE OTROS; C) DILUYENTES SELECCIONADOS ENTRE LACTOSA, MANITOL, SORBITOL, ALMIDON, ENTRE OTROS; D) ADYUVANTE DE COMPRESION SELECCIONADO ENTRE CELULOSA MICRCRISTALINA, FOSFATO CALCICO, MANITOL, LACTOSA O SORBITOL. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR CINASA p38REFERS TO A MAINTAINED RELEASE PHARMACEUTICAL COMPOSITION INCLUDING: A) 8- (2,6-DIFLOROPHENYL) -4- (4-FLUORO-2-METHYLPHENYL) -2 - {[2-HYDROXY-1- (HYDROXIMETHYL) ETHYL ] AMINO} PYRID [2,3-d] PYRIMIDIN-7 (8H) -ONE IN A PROPORTION 2.5% BY WEIGHT; B) 10 TO 70% BY WEIGHT OF RELEASE-RETARDING POLYMER SELECTED AMONG SODIUM METILCELLULOSE, HYDROXYPROPYL-CELLULOSE, CARBOXIMETHYLAMIDE, AMONG OTHERS; C) DILUENTS SELECTED AMONG LACTOSE, MANNITOL, SORBITOL, STARCH, AMONG OTHERS; D) COMPRESSION ADJUVANT SELECTED FROM MICRCRYSTALLINE CELLULOSE, CALCIUM PHOSPHATE, MANNITOL, LACTOSE OR SORBITOL. SUCH COMPOSITION IS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY KINASE p38
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73667905P | 2005-11-15 | 2005-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20100742A1 true PE20100742A1 (en) | 2010-11-25 |
Family
ID=38049392
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006001434A PE20070823A1 (en) | 2005-11-15 | 2006-11-13 | SALT 8- (2,6-DIFLUOROPHENYL) -4- (4-FLUORO-2-METHYLPHENYL) -2 - {[2-HYDROXY-1- (HYDROXIMETHYL) ETHYL] AMINO} PYRID [2,3-] PYRIMIDIN SALT -7 (8H) -ONA |
PE2010000447A PE20100743A1 (en) | 2005-11-15 | 2006-11-13 | NEW PROCEDURES AND FORMULATIONS |
PE2010000446A PE20100742A1 (en) | 2005-11-15 | 2006-11-13 | NEW PROCEDURES AND FORMULATIONS |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006001434A PE20070823A1 (en) | 2005-11-15 | 2006-11-13 | SALT 8- (2,6-DIFLUOROPHENYL) -4- (4-FLUORO-2-METHYLPHENYL) -2 - {[2-HYDROXY-1- (HYDROXIMETHYL) ETHYL] AMINO} PYRID [2,3-] PYRIMIDIN SALT -7 (8H) -ONA |
PE2010000447A PE20100743A1 (en) | 2005-11-15 | 2006-11-13 | NEW PROCEDURES AND FORMULATIONS |
Country Status (18)
Country | Link |
---|---|
US (1) | US20080268044A1 (en) |
EP (1) | EP1954282A4 (en) |
JP (1) | JP2009516000A (en) |
KR (1) | KR20080074178A (en) |
CN (3) | CN102030749A (en) |
AR (1) | AR056218A1 (en) |
AU (1) | AU2006315162A1 (en) |
BR (1) | BRPI0618581A2 (en) |
CA (1) | CA2629912A1 (en) |
CR (1) | CR9992A (en) |
EA (1) | EA200801327A1 (en) |
IL (1) | IL191482A0 (en) |
MA (1) | MA29949B1 (en) |
NO (1) | NO20082541L (en) |
PE (3) | PE20070823A1 (en) |
TW (1) | TW200738243A (en) |
WO (1) | WO2007059500A2 (en) |
ZA (1) | ZA200803987B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2426654C (en) | 2000-10-23 | 2010-12-21 | Smithkline Beecham Corporation | 2,4,8-trisubstituted-8h-pyrido[2,3-d}pyrimidin-7-one compounds |
GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
PE20061351A1 (en) * | 2005-03-25 | 2007-01-14 | Glaxo Group Ltd | 8H-PYRID [2,3-d] PYRIMIDIN-7-ONA 2,4,8-TRISUSTITUTED COMPOUNDS AS CSBP / RK / p38 KINASE INHIBITORS |
EP2032142A4 (en) * | 2006-06-16 | 2010-07-21 | Glaxo Group Ltd | Novel compounds |
JP2010500360A (en) | 2006-08-10 | 2010-01-07 | アルボア コーポレーション | Local therapy of lower respiratory inflammatory diseases with inflammatory cytokine inhibitors |
US9180198B2 (en) | 2009-09-23 | 2015-11-10 | Korea United Pharm, Inc. | Slow-release cilostazol tablet having an improved elution rate and minimal side effects |
WO2012045072A2 (en) * | 2010-10-01 | 2012-04-05 | Mary Kay Inc. | Sugar-based dispersion |
HUE052355T2 (en) | 2013-03-14 | 2021-04-28 | Amgen Inc | Heterocyclic compounds and their uses |
AU2015362790A1 (en) | 2014-12-16 | 2017-07-20 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
MX2017016231A (en) | 2015-06-10 | 2018-11-29 | Axovant Sciences Gmbh | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors. |
US10428062B2 (en) | 2015-08-12 | 2019-10-01 | Axovant Sciences Gmbh | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors |
LT3691620T (en) | 2017-10-05 | 2022-09-26 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US10980747B2 (en) * | 2017-11-27 | 2021-04-20 | Shin-Etsu Chemical Co., Ltd. | Composition for solid preparation, solid preparation, and method for producing the same |
JP6983139B2 (en) * | 2017-11-27 | 2021-12-17 | 信越化学工業株式会社 | Compositions for solid formulations, solid formulations and methods for producing them |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ322197A (en) * | 1995-11-21 | 1999-02-25 | Yamanouchi Pharma Co Ltd | Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof |
US6875769B2 (en) * | 1996-05-23 | 2005-04-05 | Pfizer Inc. | Substituted6,6-hetero-bicyclicderivatives |
US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
TR200002209T2 (en) * | 1998-01-30 | 2000-11-21 | R-Tech Ueno, Ltd. | Ophthalmic composition. |
CA2426654C (en) * | 2000-10-23 | 2010-12-21 | Smithkline Beecham Corporation | 2,4,8-trisubstituted-8h-pyrido[2,3-d}pyrimidin-7-one compounds |
EP1345603A4 (en) * | 2000-12-20 | 2004-09-08 | Merck & Co Inc | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
JP2005529060A (en) * | 2001-09-25 | 2005-09-29 | ファルマシア コーポレイション | Solid form of N- (2-hydroxyacetyl) -5- (4-piperidyl) -4- (4-pyrimidinyl) -3- (4-chlorophenyl) pyrazole |
-
2006
- 2006-11-13 TW TW095141830A patent/TW200738243A/en unknown
- 2006-11-13 PE PE2006001434A patent/PE20070823A1/en not_active Application Discontinuation
- 2006-11-13 PE PE2010000447A patent/PE20100743A1/en not_active Application Discontinuation
- 2006-11-13 PE PE2010000446A patent/PE20100742A1/en not_active Application Discontinuation
- 2006-11-14 AR ARP060104985A patent/AR056218A1/en not_active Application Discontinuation
- 2006-11-15 KR KR1020087014339A patent/KR20080074178A/en not_active Application Discontinuation
- 2006-11-15 US US12/093,191 patent/US20080268044A1/en not_active Abandoned
- 2006-11-15 EA EA200801327A patent/EA200801327A1/en unknown
- 2006-11-15 AU AU2006315162A patent/AU2006315162A1/en not_active Abandoned
- 2006-11-15 JP JP2008541460A patent/JP2009516000A/en active Pending
- 2006-11-15 CA CA002629912A patent/CA2629912A1/en not_active Abandoned
- 2006-11-15 EP EP06839884A patent/EP1954282A4/en not_active Withdrawn
- 2006-11-15 CN CN2010105052625A patent/CN102030749A/en active Pending
- 2006-11-15 WO PCT/US2006/060898 patent/WO2007059500A2/en active Application Filing
- 2006-11-15 CN CNA2006800511053A patent/CN101360497A/en active Pending
- 2006-11-15 CN CN201010505249XA patent/CN102030748A/en active Pending
- 2006-11-15 BR BRPI0618581-9A patent/BRPI0618581A2/en not_active IP Right Cessation
-
2008
- 2008-05-09 ZA ZA200803987A patent/ZA200803987B/en unknown
- 2008-05-15 MA MA30928A patent/MA29949B1/en unknown
- 2008-05-15 IL IL191482A patent/IL191482A0/en unknown
- 2008-05-20 CR CR9992A patent/CR9992A/en not_active Application Discontinuation
- 2008-06-06 NO NO20082541A patent/NO20082541L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1954282A2 (en) | 2008-08-13 |
PE20070823A1 (en) | 2007-08-09 |
AR056218A1 (en) | 2007-09-26 |
CN102030748A (en) | 2011-04-27 |
US20080268044A1 (en) | 2008-10-30 |
AU2006315162A1 (en) | 2007-05-24 |
JP2009516000A (en) | 2009-04-16 |
BRPI0618581A2 (en) | 2011-09-06 |
MA29949B1 (en) | 2008-11-03 |
PE20100743A1 (en) | 2010-11-25 |
NO20082541L (en) | 2008-08-14 |
KR20080074178A (en) | 2008-08-12 |
CN101360497A (en) | 2009-02-04 |
EP1954282A4 (en) | 2011-10-12 |
CR9992A (en) | 2008-07-29 |
TW200738243A (en) | 2007-10-16 |
WO2007059500A2 (en) | 2007-05-24 |
IL191482A0 (en) | 2009-02-11 |
CA2629912A1 (en) | 2007-05-24 |
WO2007059500A3 (en) | 2007-11-22 |
ZA200803987B (en) | 2009-12-30 |
CN102030749A (en) | 2011-04-27 |
EA200801327A1 (en) | 2009-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20100742A1 (en) | NEW PROCEDURES AND FORMULATIONS | |
UY27878A1 (en) | INDOLINFENYL SULFONAMIDE DERIVATIVES | |
CL2007001166A1 (en) | Compounds derived from condensed pyrimidine, pi3-kinase inhibitors; processes to prepare the compounds; pharmaceutical composition that includes them; use of the compounds in the preparation of medicaments; process to prepare the pharmaceutical composition; and kit that includes the pharmaceutical composition | |
CR9748A (en) | DERIVATIVES OF XANTINA AS SELECTIVE AGONISTS OF HM74A | |
CL2007001165A1 (en) | 2- (1h-indazol-4-yl) -6- (4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-thieno [3,2-d] pyrimidine; preparation procedure; pharmaceutical composition; process of preparing said composition; pharmaceutical kit; and use to treat diseases such as cancer, immune disorders and cardiovascular diseases. | |
ECSP088973A (en) | IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHETIC KINASE GLYCOGEN (GSK3) | |
UA86614C2 (en) | Compound having kinase ingibitor activity, pharmaceutical composition containing thereof and use thereof for the preparation of medicine | |
DOP2002000429A (en) | IMIDAZOTRIAZINAS | |
TW200637614A (en) | Bendamustine pharmaceutical compositions | |
TW200508235A (en) | Substituted hexahydropyrazino[1, 2-a]pyrimidine-4, 7-dione derivatives, processes for their preparation and their use as medicaments | |
UY27755A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND INHIBITORS. | |
HN2008001530A (en) | AMINO PYRIMIDINE COMPOUNDS 2.6- SUBSTITUTED -4-MONOSUSTITUTED AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEIVER | |
ECSP077324A (en) | BICYCLIC AMIDAS AS INHIBITORS OF CINASA | |
ECSP088974A (en) | IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN (GSK3) | |
DOP2006000082A (en) | ASENAPINE MALEATE ORTHROBOMIC CRYSTAL FORM AND ITS USE IN THE TREATMENT OF MENTAL DISORDERS. | |
MA32070B1 (en) | Fusion-bonded heterocyclic derivatives and methods of use thereof | |
MX2010009414A (en) | Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease. | |
PA8586001A1 (en) | INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | |
CU23208A3 (en) | OXAZOLIDINONAS REPLACED AND ITS USE IN THE FIELD OF THE SANGUINEA COAGULATION | |
BRPI0414948A (en) | pyrazolo-e-imidazo pyrimidine derivatives | |
CR10092A (en) | NEW SUBSTITUTED ACICLIC FUROPIRIMIDINE DERIVATIVES AND THEIR USE | |
WO2002070532A3 (en) | C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses | |
AR059864A1 (en) | BENZAMIDA COMPOSITE PHARMACEUTICAL COMPOSITION UNDERSTANDING ITS USE TO PREPARE A MEDICINAL PRODUCT AND PROCEDURES FOR ITS PREPARATION | |
EA201070195A1 (en) | DERIVATIVES 1,2,3,4-TETRAGIDROPYRROLO [1,2-A] PIRAZIN-6-CARBOXAMIDES AND 2,3,4,5-TETRAHYDROPYRROLO [1,2-a] [1,4] -DIAZEPIN-7-CARBOXAMIDES , THEIR RECEIVING AND THEIR APPLICATION IN THERAPY | |
UA86873C2 (en) | SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |